Research Overview
Circadian signalling
The nightly melatonin rise is the best-characterised internal time signal in mammals. Melatonin feeds back onto MT1 and MT2 receptors expressed densely in the suprachiasmatic nucleus and the pars tuberalis, and experimental work uses the molecule to phase-shift free-running rhythms, to probe the phase-response curve, and to study photoperiodic responses in seasonal breeders. Because light suppresses endogenous release, dim-light melatonin onset has become a standard phase marker in human chronobiology studies.
Receptor pharmacology
MT1 and MT2 are Gi-coupled and lower cyclic AMP, but their downstream roles differ: rodent work generally associates MT1 with acute neuronal firing suppression in the SCN and MT2 with phase-shifting. Selective ligands and receptor-knockout models are used to separate the two, and approved chronobiotic drugs such as ramelteon and agomelatine were developed against these same targets, which gives the field a well-mapped pharmacological reference set.
Redox and mitochondrial research
Separately from receptor signalling, melatonin and its metabolites AFMK and AMK have been examined as direct scavengers of hydroxyl radical, peroxynitrite and related species. Reported observations in cell and animal models include:
- Accumulation in mitochondria and effects on membrane potential in stressed preparations
- Changes in antioxidant enzyme expression, including superoxide dismutase and glutathione peroxidase
- Attenuation of lipid peroxidation markers in ischaemia–reperfusion and toxin models
- Interest in local synthesis outside the pineal gland, including gut and immune tissue
Practical limits
Melatonin is degraded rapidly by light and oxidises in solution, and its plasma half-life is short, which complicates exposure modelling. Investigators comparing results across studies typically record light conditions, vehicle composition and the timing of sampling, because all three materially change what is measured.
